CorMedix (CRMD) Q3 2024 earnings summary

Executive summary

• Achieved $11.5 million in Q3 2024 net revenue, driven by DefenCath's first full quarter of sales following outpatient launch in July 2024 and inpatient launch in April 2024.

• Signed agreements with two mid-size and one large dialysis operator, expanding access to 60% of U.S. outpatient dialysis clinics.

• Outpatient adoption is protocol-driven, leading to rapid patient conversion, while inpatient uptake is progressing more slowly due to complex hospital protocols.

• Net loss for Q3 2024 was $2.8 million, a 72% improvement year-over-year, driven by product launch.

• DefenCath is the first and only FDA-approved antimicrobial catheter lock solution in the U.S., with exclusivity through 2033 and potential patent protection through 2042.

Financial highlights

• Q3 2024 net revenue: $11.5 million; nine-month 2024 net revenue: $12.3 million.

• Q3 2024 net loss: $2.8 million ($0.05/share) vs. $9.7 million ($0.17/share) in Q3 2023; nine-month net loss: $31.4 million ($0.54/share) vs. $31.6 million ($0.65/share) in 2023.

• Gross profit for Q3 2024: $10.8 million; gross margin approximately 94%.

• Operating expenses for Q3 2024: $14.1 million, up 33–34% year-over-year, mainly from higher selling, marketing, and G&A costs.

• Cash and equivalents at $46.0 million as of September 30, 2024; $12.4–13.4 million raised via ATM in Q3.

Outlook and guidance

• Management expects to be EBITDA positive in Q4 2024, with sufficient resources to fund operations for at least 12 months from Q3 2024 report issuance.

• Operating expenses for Q4 projected in the $15–17 million range.

• Plans include expanding DefenCath indications, launching an Expanded Access Program by year-end, and starting new clinical studies in early 2025.

• Inpatient revenue contribution expected to be long-term, with outpatient driving near-term growth.